rpn502 Antibody

What is RPN2 and why is it important in cellular biology?

RPN2 (also known as Ribophorin II, Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2, or RPN-II) functions as a key subunit of the oligosaccharyl transferase (OST) complex. This complex catalyzes the initial transfer of glycans (specifically Glc(3)Man(9)GlcNAc(2) in eukaryotes) from lipid carrier dolichol-pyrophosphate to asparagine residues within the Asn-X-Ser/Thr consensus motif in nascent polypeptide chains. This process represents the critical first step in protein N-glycosylation, which occurs cotranslationally as proteins are being synthesized. The OST complex associates directly with the Sec61 complex at the channel-forming translocon complex that mediates protein translocation across the endoplasmic reticulum (ER). All subunits, including RPN2, are essential for achieving maximal enzymatic activity of the OST complex .

What experimental applications is the RPN2 antibody suitable for?

The RPN2 antibody (such as the rabbit polyclonal ab244399) has been validated and is suitable for multiple experimental applications including:

• Immunohistochemistry on paraffin-embedded sections (IHC-P)

• Western blotting (WB)

• Immunocytochemistry/Immunofluorescence (ICC/IF)

The antibody has been cited in multiple scientific publications, indicating its reliability and acceptance in the research community. The specific applications may vary between different commercial antibodies, so researchers should verify the validation data for their specific antibody product .

What is the immunogen used for generating RPN2 antibody?

The RPN2 antibody (ab244399) is generated using a recombinant fragment protein corresponding to amino acids 300-500 of human Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2. This region was selected as an optimal immunogen for antibody production. When designing experiments, researchers should be aware of this epitope location, as it may impact detection of truncated forms or specific domains of the protein .

How should I validate the specificity of the RPN2 antibody in my experimental system?

Validating antibody specificity is crucial for reliable results. For RPN2 antibody, consider these validation approaches:

• Positive and negative controls: Include cell lines or tissues known to express high levels of RPN2 (positive control) and those with minimal expression (negative control).

• Immunoprecipitation followed by mass spectrometry: This can confirm the antibody is pulling down the correct protein.

• siRNA or CRISPR knockdown: Reduce RPN2 expression and confirm decreased signal with your antibody.

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide before application to your samples. The peptide should block specific binding.

• Cross-reactivity testing: If working with non-human samples, test specificity across species if sequence homology suggests potential reactivity .

What are the recommended experimental conditions for Western blotting with RPN2 antibody?

For optimal Western blot results with RPN2 antibody:

• Sample preparation: Extract proteins under conditions that preserve the native state of membrane-associated proteins. RPN2 is located in the ER membrane, so consider using detergent-based lysis buffers (e.g., RIPA or NP-40) with protease inhibitors.

• Protein loading: Load 20-30 μg of total protein per lane for cell lysates.

• Gel percentage: Use 10-12% polyacrylamide gels, as RPN2 has a molecular weight of approximately 63 kDa.

• Transfer conditions: Transfer to PVDF or nitrocellulose membranes using standard protocols (wet transfer recommended for membrane proteins).

• Blocking: Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody dilution: Typically 1:1000-1:2000 dilution (verify optimal dilution for your specific antibody).

• Incubation: Overnight at 4°C for primary antibody, 1-2 hours at room temperature for secondary antibody.

• Expected band size: The RPN2 protein should appear at approximately 63 kDa .

What controls should I include when using RPN2 antibody for immunohistochemistry?

For rigorous immunohistochemistry experiments with RPN2 antibody:

• Positive tissue control: Include tissues known to express RPN2, such as liver or pancreas sections.

• Negative control: Omit primary antibody but perform all other steps identically.

• Isotype control: Use an irrelevant antibody of the same isotype and concentration.

• Absorption control: Pre-incubate the antibody with excess immunizing peptide.

• Subcellular localization verification: RPN2 should demonstrate a reticular pattern consistent with ER localization. Co-staining with other ER markers can confirm correct subcellular localization.

• Cross-reactivity assessment: If examining multiple species, include appropriate controls for each .

How can RPN2 antibody be used to study N-glycosylation defects in disease models?

RPN2 antibody can serve as a powerful tool for investigating N-glycosylation abnormalities in various disease contexts:

• Comparative expression analysis: Examine RPN2 protein levels between normal and diseased tissues using Western blotting or IHC to identify alterations in the N-glycosylation machinery.

• Co-immunoprecipitation studies: Use RPN2 antibody to pull down the OST complex and identify interacting partners or composition changes in disease states.

• Proximity ligation assays: Combine RPN2 antibody with antibodies against other glycosylation machinery components to detect protein-protein interactions and their alterations in disease.

• ER stress response analysis: Study how RPN2 expression and localization changes during ER stress conditions, which often accompany glycosylation defects.

• Drug response studies: Monitor RPN2 expression/localization changes in response to drugs targeting N-glycosylation pathways.

• Glycoproteomic analysis: Use RPN2 antibody in conjunction with glycoprotein enrichment methods to characterize changes in the N-glycoproteome in disease models .

How can I investigate the interaction between RPN2 and the Sec61 translocon complex?

To study the functional relationship between RPN2 and the Sec61 translocon:

• Co-immunoprecipitation: Use RPN2 antibody to precipitate RPN2 and associated proteins, then probe for Sec61 components by Western blot.

• Proximity labeling: Employ BioID or APEX2 systems fused to RPN2 to identify proteins in close proximity within the intact cellular environment.

• FRET/FLIM analysis: Use fluorescently tagged RPN2 and Sec61 components to measure their interaction dynamics in live cells.

• Cross-linking mass spectrometry: Apply chemical crosslinkers to stabilize RPN2-Sec61 interactions before immunoprecipitation and mass spectrometry analysis.

• Cryo-electron microscopy: Use RPN2 antibody for immunogold labeling to visualize the spatial relationship between RPN2 and Sec61 in the ER membrane.

• Functional assays: Assess how RPN2 knockdown affects protein translocation across the ER using reporter substrates known to utilize the Sec61 channel .

What approaches can be used to study the role of RPN2 in cancer progression?

RPN2 has emerging roles in cancer biology, which can be investigated using these approaches:

• Expression correlation analysis: Assess RPN2 protein levels by IHC or Western blot across tumor stages and correlate with clinical outcomes.

• Glycosylation profiling: Combine RPN2 knockdown with glycan analysis techniques to identify specific N-glycosylation events dependent on RPN2 in cancer cells.

• Drug resistance mechanisms: Investigate how RPN2 may contribute to chemoresistance by altering glycosylation of drug transporters or receptors.

• Cell migration and invasion assays: Examine how RPN2 modulation affects cancer cell motility and invasiveness, potentially through altered glycosylation of adhesion molecules.

• Xenograft models: Use RPN2 antibody for ex vivo analysis of tumor tissues from animal models with RPN2 modulation.

• Patient-derived organoids: Apply RPN2 antibody in immunofluorescence studies of 3D culture systems to assess expression patterns in more physiologically relevant models .

What are common causes of non-specific binding when using RPN2 antibody?

Non-specific binding in RPN2 antibody applications may result from:

• Insufficient blocking: Increase blocking time or concentration, or try alternative blocking agents (BSA, casein, or commercial blocking buffers).

• Overly high antibody concentration: Perform a dilution series to determine optimal concentration that maximizes specific signal while minimizing background.

• Cross-reactivity with similar epitopes: RPN2 shares structural features with other ER-resident glycosyltransferases. Verify specificity using knockout controls or peptide competition.

• Sample preparation issues: Incomplete fixation or overfixation can create artifacts. Optimize fixation protocols for your specific sample type.

• Detection system background: Switch to a more specific secondary antibody or consider using directly conjugated primary antibodies.

• Endogenous biotin or peroxidase activity: Include appropriate quenching steps in your protocol if using avidin-biotin or HRP-based detection methods .

How should I interpret conflicting RPN2 antibody results between different experimental techniques?

When facing contradictory results across different applications:

• Consider epitope accessibility: The RPN2 epitope (aa 300-500 for ab244399) may be differentially accessible in various experimental contexts. Western blotting involves denatured proteins, while IHC and ICC maintain some structural elements.

• Evaluate fixation effects: Different fixatives (formaldehyde, methanol, etc.) can variably affect epitope recognition. Test multiple fixation methods if possible.

• Assess protocol differences: Buffer compositions, incubation times, and detection methods can impact results. Standardize protocols across experiments.

• Verify with orthogonal methods: Confirm protein expression using mRNA analysis (RT-PCR, RNAseq) or alternative antibodies targeting different epitopes.

• Consider post-translational modifications: RPN2 undergoes glycosylation and other modifications that may affect antibody binding in certain contexts.

• Document all experimental variables: Create a comprehensive record of experimental conditions to identify potential sources of variability .

What quantification methods are most appropriate for RPN2 expression analysis?

For accurate quantification of RPN2 expression:

• Western blot densitometry:

  • Normalize RPN2 signal to appropriate loading controls (β-actin, GAPDH, or preferably other ER resident proteins)

  • Ensure signal is within the linear range of detection

  • Include a standard curve of recombinant protein or serial dilutions of a positive control

• Immunohistochemistry quantification:

  • Use digital image analysis software with appropriate segmentation

  • Score both intensity and percentage of positive cells

  • Employ H-score or Allred scoring systems for semi-quantitative analysis

  • Consider automated systems for unbiased assessment

• Flow cytometry:

  • Permeabilize cells appropriately for intracellular ER proteins

  • Use median fluorescence intensity rather than percent positive cells

  • Include fluorescence minus one (FMO) controls

• Statistical analysis:

  • Apply appropriate statistical tests based on data distribution

  • Consider biological replicates rather than technical replicates for power calculations

  • Report effect sizes alongside p-values

How can I use RPN2 antibody to investigate ER stress responses?

The oligosaccharyl transferase complex, including RPN2, plays critical roles during ER stress conditions. To study this relationship:

• Stress induction time course: Treat cells with ER stressors (tunicamycin, thapsigargin, DTT) and monitor RPN2 expression and localization changes over time using Western blot and ICC.

• Co-localization with stress markers: Perform dual immunofluorescence with RPN2 antibody and markers of the unfolded protein response (BiP/GRP78, CHOP, XBP1).

• Polysome association: Investigate whether RPN2 mRNA translation is altered during ER stress using polysome profiling followed by RT-PCR.

• Stress granule analysis: Determine if RPN2 relocates to stress granules during cellular stress responses using co-staining with stress granule markers.

• Chaperone interactions: Examine how RPN2 interactions with ER chaperones change during stress conditions using co-immunoprecipitation.

• Proteasomal degradation: Assess whether RPN2 stability is affected during ER stress by treating with proteasome inhibitors (MG132) and monitoring protein levels .

What are appropriate methodologies for using RPN2 antibody in high-throughput screening applications?

For adapting RPN2 antibody to high-throughput approaches:

• Automated immunofluorescence:

  • Optimize antibody concentration for automated liquid handlers

  • Develop robust image analysis algorithms for quantifying RPN2 expression/localization

  • Consider high-content screening platforms for multiplexed analysis

• Reverse-phase protein arrays (RPPA):

  • Validate RPN2 antibody specificity in lysate dilution series

  • Optimize spotting and detection conditions for your specific platform

  • Incorporate appropriate normalization controls

• Flow cytometry screening:

  • Develop permeabilization protocols compatible with automated samplers

  • Consider fluorophore-conjugated primary antibodies to reduce protocol steps

  • Implement machine learning algorithms for data analysis

• ELISA-based screening:

  • Validate sandwich ELISA configurations using RPN2 antibody

  • Establish standard curves for quantitative analysis

  • Determine minimum detection thresholds

• Data analysis considerations:

  • Implement appropriate quality control metrics

  • Utilize positive (RPN2 overexpression) and negative (RPN2 knockdown) controls

  • Apply robust statistical methods suitable for large datasets

How does the RPN2 antibody performance compare across different species?

Note: Species reactivity predictions are based on sequence homology, but specific validation is recommended before extensive use in any non-human species. Optimization of protocols may be necessary when working with predicted species .

What technical differences should I consider when choosing between monoclonal and polyclonal RPN2 antibodies?

When selecting an RPN2 antibody, consider your specific application requirements, the importance of reproducibility, and whether detection of multiple epitopes is advantageous for your research question .

How might RPN2 antibodies contribute to emerging glycobiology research?

RPN2 antibodies are poised to play important roles in advancing glycobiology through:

• Single-cell glycomics: Combining RPN2 immunostaining with single-cell analysis technologies to understand cell-to-cell variation in N-glycosylation machinery.

• Spatial glycomics: Using RPN2 antibody in multiplexed imaging to map the organization of glycosylation machinery within cellular microdomains.

• Glycan-dependent disease biomarkers: Employing RPN2 antibody alongside glycan analysis to identify disease-specific alterations in the N-glycosylation pathway.

• Therapeutic targeting: Facilitating the development of drugs that modulate specific aspects of N-glycosylation by providing tools to monitor RPN2 and OST complex activity.

• Organoid and 3D culture systems: Applying RPN2 antibody in advanced culture models to understand glycosylation dynamics in more physiologically relevant contexts.

• CRISPR screening readouts: Using RPN2 antibody-based assays as phenotypic readouts in genetic screens targeting glycosylation pathways .

What methodological innovations might improve RPN2 antibody applications?

Several technological advances could enhance RPN2 antibody utility:

• Nanobody development: Smaller antibody fragments against RPN2 could improve tissue penetration and allow for super-resolution microscopy applications.

• Proximity labeling tools: RPN2 antibody conjugated to enzymes like APEX2 or TurboID could help identify transient interaction partners.

• Antibody engineering: Site-specific conjugation of fluorophores or other detection tags could improve signal-to-noise ratios.

• Microfluidic applications: Integration with organ-on-chip platforms could enable real-time monitoring of RPN2 dynamics.

• Intrabody development: Cell-penetrating variants of RPN2 antibodies could allow for live-cell imaging and functional perturbation.

• Complementation assays: Split reporter systems based on RPN2 binding could enable visualization of protein complex formation in living cells .